Status:
COMPLETED
A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Renal Transplantation
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The hypothesis of this study is that lymphocyte depletion by Campath-1H and rituximab will obviate the need for long-term calcineurin inhibitors in renal transplantation. Most successful strategies to...
Eligibility Criteria
Inclusion
- renal transplant recipients
Exclusion
- Recipients of HLA-identical living-donor renal transplants;
- multi-organ transplant;
- known hypersensitivity to Campath-1H, Rituximab, CellCept, or prednisone;
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00214266
Start Date
January 1 2005
End Date
September 1 2007
Last Update
May 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin
Madison, Wisconsin, United States, 53792